Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Period	fcf
2015-12-31	-$84.28M
2016-12-31	-$123.42M
2017-12-31	-$90.09M
2018-12-31	$706.62M
2019-12-31	-$354.97M
2020-12-31	-$320.55M
2021-12-31	-$427.65M
2022-12-31	-$296.49M
2023-12-31	-$192.61M
2024-12-31	-$175.71M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NKTR	$77.85	+0.00%	0.46M
3
4
5

Nektar Therapeutics (NKTR) Free Cash Flow

Free Cash Flow Data

Get Nektar Therapeutics Data in Excel

More NKTR Financial Data